Putnam BioRevolution ETF
SYNB
New York Stock Exchange Arca- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- United States of America
- IPO Date
- Sep 30, 2022
- Similar Companies
- Business
- Putnam BioRevolution ETF (NYSE Arca: SYNB) is an actively managed exchange-traded fund that seeks long-term capital appreciation by investing primarily in common stocks of companies worldwide benefiting from the biology revolution; it maintains a concentrated portfolio of 30-50 high-conviction holdings selected through collaborative research by Putnam sector analysts and the Sustainable Equity team, with a benchmark-agnostic approach focused on growth and value stocks across all market capitalizations. The fund targets companies at the intersection of technology and biology, including technology-enabling firms, synthetic biology innovators, and those in industries transformed by biological advancements such as health care, materials, information technology, and consumer staples; top sectors include health care (58.90%), materials (20.43%), and information technology (8.92%), with leading holdings like Thermo Fisher Scientific, Corteva, and AbbVie. Launched on September 29, 2022, and managed by William Rives, the ETF is sponsored by Putnam Investments, a Franklin Templeton company headquartered in Boston, Massachusetts, with global operations through Franklin Templeton's network in major financial markets. In a significant recent development, Franklin Templeton announced on September 19, 2025, plans to liquidate the fund on or about November 21, 2025, due to low assets under management of approximately $1.58 million; trading on NYSE Arca was suspended prior to market open on November 14, 2025, with no purchase or redemption orders accepted after October 24 and November 13, 2025, respectively. The net expense ratio stands at 0.71%, with annual dividend distributions and a Morningstar rating of 3 stars in the Health category.